$MEDS

DataMeds AI signed a non-binding LOI with six companies to acquire assets, licenses, and a controlling stake in HLH. The deal, pending approvals, would give the recipients 89.5% ownership, with shares as consideration. Closing is contingent on definitive agreements and a liability cap of $2 million. The LOI also includes royalty and governance terms, with REBOOT's transactions potentially closing separately.

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies ● Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastruc

DataMEDS AI, Inc. (MEDS) introduced its 'Health Lives Here' Community Respiratory Program, targeting 6,500+ Corexa Health network pharmacies. The program, set to launch in Q4 2026, aims to improve respiratory season practices, telehealth access, and pharmacist education. It will focus on COVID and other respiratory disease tests, vaccines, and antivirals.

DataMEDS AI (NASDAQ:MEDS) launched the 'Health Lives Here' Community Respiratory Program to improve access to respiratory disease vaccines, diagnostics, and therapeutics in 6,500+ independent pharmacies. The program prioritizes Nuvaxovid, offers testing, telehealth, and access to FDA-approved antivirals, aiming to enhance community health, especially in rural areas. Revenue streams include vaccine sales, telehealth services, and testing.

DataMEDS AI (NASDAQ:MEDS) announced a non-binding LOI with Datavault AI (NASDAQ:DVLT), others, to acquire QOLPOM IP and expand its healthcare ecosystem. The deal aims to integrate health tracking, prescription delivery, and AI/blockchain tech, with a Q4 2026 target close. FDA guidance supports the optimization of DataMEDS' Health Lives Here app. The transaction is subject to due diligence and regulatory approvals.

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PRESS RELEASE DATAMEDS AI, INC. (DBA DATAMEDS SI) 3000 BAYPORT DRIVE, SUITE 950 TAMPA, FLA. 33607 www.datamedsai.com RUBENSTEIN PUBLIC RELATIONS CONTACT: JAMES LAMBERT 212-805-3024 JLAMBERT@RUBENSTEINPR.COM FOR IMMEDIATE RELEASE DATAMEDS REGAINS COMPLIANCE WITH NASDA

DataMeds AI (NASDAQ:MEDS) announced it has regained compliance with NASDAQ's minimum stockholders' equity requirement of $2.5 million. The company previously faced delisting for failing to meet this threshold and a $1 bid price. NASDAQ confirmed compliance after recent Form 8-K filings showed equity exceeding $2.5 million. Continued compliance depends on future periodic reports.

DataMeds AI Inc. (NASDAQ: MEDS) stock surged 16.32% after securing Humana Medicaid coverage for its ChemoFx assay and reporting $1M in September revenue. The company also launched a GLP-1 focused app, driving investor interest. Despite weak fundamentals, including negative cash flow and equity, MEDS trades on news catalysts, with significant volatility.

DataMeds AI (MEDS) received a Nasdaq deficiency notice for not meeting the $2.5M stockholders' equity requirement. The company claims to have resolved this by converting payables to equity and completing other transactions, awaiting Nasdaq's confirmation. Nasdaq may delist if future reports show non-compliance.

DataMeds AI secured an exclusive U.S. license for REBOOT Health AI's platform to enhance its GLP-1 weight management solution. The deal includes a revenue-sharing model and $2M in stock issuance. The perpetual license runs until the last patent expires, with restrictions on source code access and modifications.